LATS2 and cancer: Targeting this pathway enhances the efficacy of EGFR and GCLM inhibitors, suggesting a new therapeutic strategy against aggressive cancers.[104] Similarly, LATS2 phosphorylates ALKBH5, enhancing its stability and nuclear retention, which in turn demethylates m6A from LATS2 mRNA, stabilizing the transcript.